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Background: Although Duchenne and Becker muscular dystrophies, X-linked recessive myopathies, predominantly
affect males, a clinically significant proportion of females manifesting symptoms have also been reported. They
represent an heterogeneous group characterized by variable degrees of muscle weakness and/or cardiac
involvement. Though preferential inactivation of the normal X chromosome has long been considered the principal
mechanism behind disease manifestation in these females, supporting evidence is controversial.
Methods: Eighteen females showing a mosaic pattern of dystrophin expression on muscle biopsy were recruited
and classified as symptomatic (7) or asymptomatic (11), based on the presence or absence of muscle weakness. The
causative DMD gene mutations were identified in all cases, and the X-inactivation pattern was assessed in muscle
DNA. Transcriptional analysis in muscles was performed in all females, and relative quantification of wild-type and
mutated transcripts was also performed in 9 carriers. Dystrophin protein was quantified by immunoblotting in 2
females.
Results: The study highlighted a lack of relationship between dystrophic phenotype and X-inactivation pattern in
females; skewed X-inactivation was found in 2 out of 6 symptomatic carriers and in 5 out of 11 asymptomatic
carriers. All females were characterized by biallelic transcription, but no association was found between
X-inactivation pattern and allele transcriptional balancing. Either a prevalence of wild-type transcript or equal
proportions of wild-type and mutated RNAs was observed in both symptomatic and asymptomatic females.
Moreover, very similar levels of total and wild-type transcripts were identified in the two groups of carriers.
Conclusions: This is the first study deeply exploring the DMD transcriptional behaviour in a cohort of female
carriers. Notably, no relationship between X-inactivation pattern and transcriptional behaviour of DMD gene was
observed, suggesting that the two mechanisms are regulated independently. Moreover, neither the total DMD
transcript level, nor the relative proportion of the wild-type transcript do correlate with the symptomatic
phenotype.
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Duchenne and Becker muscular dystrophies (DMD,
MIM#310200 and BMD, MIM#300376) are X-linked re-
cessive conditions caused by mutations in the dystrophin
gene. Both DMD and BMD usually affect males, with
the majority of female carriers of DMD mutations being
asymptomatic, often presenting with high serum creatine
kinase (CK) levels as the only clinical sign. Nevertheless,
a certain number of female carriers, defined as “mani-
festing” or “symptomatic”, do develop symptoms of the
disease, which vary from a mild muscle weakness to a
DMD-like clinical course; the muscle weakness is gener-
ally asymmetric and proximally distributed, and the age
of onset is extremely variable [1,2]. Manifesting carriers
may also present cardiac pathology (dilated cardiomyop-
athy), either alone or in addition to the muscle weakness
[3,4]. The percentage of symptomatic carriers has been
estimated in the range of 2.5-7.8% [1,2], based on skel-
etal muscle clinical involvement. In contrast, a study
conducted in the Netherlands, taking into account not
only muscle symptoms but also pure cardiac presenta-
tion, revealed a higher proportion of carriers manifesting
symptoms, i.e. 22% [5].
Peculiar chromosomal aberrations are well known to
be associated with clinical manifestations in DMD female
carriers; for example Turner syndrome (45,X) associated
with a DMD gene mutation on the single X chromosome
[6], uniparental disomy of the X chromosome carrying
the DMD mutation [7] and balanced X-autosome trans-
locations with a breakpoint in the dystrophin gene.
X chromosome inactivation (XCI) represents the tran-
scriptional silencing of the majority of genes on one of
the X chromosomes in mammalian females. The choice
of the X chromosome to be inactivated occurs in an
early stage during embryonic development and the
process is random and clonally inherited. Skewed X-
inactivation is the preferential inactivation of one of the
two X chromosomes; it may occur either by chance
(primary non-random X-inactivation) or as a result of
secondary cell selection [8,9]. In the case of carriers of
X-autosome translocations, it is generally accepted that
the manifestations of the disease result from a non-
random X-inactivation pattern, with the derivative X
remaining active as a saving mechanism against the
monosomy of autosomal regions [10,11]. Different pat-
terns of X-inactivation have also been demonstrated in
pairs of clinically discordant monozygotic female twins
heterozygous for dystrophin gene mutations [12-14].
Based on this evidence, skewed X-inactivation has clas-
sically been considered as the mechanism most likely
to explain the dystrophic phenotype in female carriers,
and this hypothesis has been lent weight by various
X-inactivation studies performed on DNA from peripheral
blood lymphocytes [15,16]. Nevertheless, other studiesbased on X-inactivation tests, performed on either
peripheral blood [17-20] or muscle tissue [21], have
highlighted the absence of a clear correlation between
X-inactivation pattern and phenotype, reporting mani-
festing carriers with both skewed and completely ran-
dom X-inactivation.
Hence, in order to explore the controversial issue of
the pathogenic mechanism underlying clinical manifest-
ation in DMD female carriers, we set out to compare
the X-inactivation pattern with DMD allele transcription
balancing in muscle tissue from 7 symptomatic and 11
asymptomatic carriers featuring fully characterized
DMD gene mutations.
Surprisingly, this analysis revealed a complete lack of
relationship between X-inactivation, transcription balan-
cing and phenotype. In fact, the occurrence of skewed
X-inactivation in muscle, inferred by studying androgen
receptor (AR) gene methylation status, did not correlate
with the symptomatic phenotype. In addition, transcrip-
tional representation of the mutated DMD alleles in
muscle failed to mirror the X-inactivation pattern, sug-
gesting that these two mechanisms are independently
regulated. In conclusion, neither skewed X-inactivation
nor preferential expression of the mutated DMD allele
enables prediction of a dystrophinopathic phenotype.Methods
Sample
Eighteen females presenting a mosaic pattern of dys-
trophin expression under immunohistochemical analysis
were enrolled in the study, which was approved by the
local ethics committee (document n.9/2005).
Females were recruited in the course of regular NM
clinic in different collaborating centers in the period be-
tween 2004 and 2010, and they underwent muscular biopsy
due to persistent high CK or other signs and symptoms of
the disease. All the analysed females were unrelated cases.
According to the literature, female carriers were classi-
fied as (1) symptomatic, when presenting with muscle
weakness and/or dilated cardiomyopathy or (2) asymp-
tomatic, when characterized by the presence of high CK
levels and/or minor myopathic signs like muscle cramps
and myalgia, but no muscle weakness or dilated cardio-
myopathy [5,19].Mutation Analysis
Genomic DNA was extracted from peripheral blood by
Biorobot Qiagen (Qiagen, Chatsworth, CA), after informed
consent.
Mutation analysis was performed by Multiplex
Ligation-dependent Probe Amplification (MLPA), to de-
tect deletions and duplications, and direct sequencing,
to identify point mutations. MLPA analysis was carried
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manufacturer’s recommendations (MRC Holland, Amster-
dam, Netherlands), thereby consenting the copy-number
screening of all 79 dystrophin exons. PCR products were
analysed on an ABI 3130 automated sequencer using
Genescan software (Applied Biosystems). The dosage quo-
tient was calculated as previously described [22].
For sequence analysis, dystrophin exons, including 3’
and 5’ intron boundaries, were PCR amplified. Amplifi-
cation reactions were performed as previously described
[23]. All PCR products were purified and sequenced on
an ABI 3130 automated sequencer.
Comparative Genomic Hybridization (CGH) analysis
by DMD-CGH microarray was performed as previously
described [24].
X-inactivation Studies
Genomic DNA was extracted from muscle tissue using the
QIAblood Kit procedure (Qiagen, Chatsworth, CA). The
(CAG)n repeat at the AR locus was PCR-amplified in a re-
action containing: 200 ng DNA, 10 mM Tris–HCl, 50 mM
KCl, 1.5 mM MgCl2, 0.2 mM of each dNTP, 175 ng of each
primer (forward: 5’-TCCAGAATCTGTTCCAGAGCGTG-
3’; reverse: 5’-CTGTGAAGGTTGCTGTTCCTCAT-3’),
1.25U Taq polymerase (Invitrogen), under the following
conditions: 94°C for 5 min; 28 cycles of 94°C for 45 sec,
60°C for 30 sec, 72°C for 30 sec. Amplification products
were analyzed on an ABI 3130 automated sequencer
and AR alleles were determined by Genemapper software
(Applied Biosystems). The X-inactivation pattern was
investigated in carriers informative for the (CAG)n
repeat. Analysis was performed in duplicates by semi-
quantification of the relative inactivation of AR alleles [15].
1 μg of DNA was digested with 10U HpaII and 10U CfoI
(Boehringer Mannheim) for 2 h at 37°C. Enzymes were
heat-inactivated and digested DNA samples were purified
with Microcon columns; 200 ng were amplified as
described above. PCR products from undigested and
digested samples were run in parallel on ABI 3130 sequen-
cer. The ratio between the two alleles of the undigested
sample was calculated and the resulting correction factor
was applied to allele values in the digested samples. The
degree of X-inactivation was calculated by normalizing the
sum of the two alleles in the digested sample to 100%.
Results obtained from either peak height or peak area
were compared and very similar values were obtained.
X-inactivation pattern was considered as random for
ratios ≤80:20, moderately skewed for ratios >80:20 and
≤90:10, and highly skewed for ratios >90:10, according
to Amos-Landgraf et al., 2006 [25].
RNA Analysis
Total RNA was isolated from skeletal muscle biopsy
samples using the RNeasy Kit (Qiagen, Chatsworth, CA)according to the manufacturer’s instructions. Reverse
transcription and cDNA amplification (RT-PCR) was
performed as previously described [23]. The dystrophin
transcript was analysed using appropriate pairs of oligo-
nucleotides (sequences are available upon request). All
PCR fragments were purified and sequenced.
In order to assess the proportion of wild-type vs.
deleted/duplicated transcripts, a relative quantification
was performed using an Agilent High Sensitivity DNA
chip (Agilent Technologies, Santa Clara, CA), which
allows the sizing and quantification of cDNA samples in
the 5–500 pg/μL concentration range. Different numbers
of amplification cycles were tested: 25 cycles reactions
were performed in order to avoid quantification during
the plateau phase of PCR. Amplification products were
analysed by an Agilent 2100 Bioanalyzer. The relative
percentages were calculated as the ratio between each
type of transcript (wild-type or mutated) and the sum of
all transcripts (wild-type +mutated).
A relative quantification of dystrophin transcript was
performed by real-time PCR. Taqman probes specific for
dystrophin exon 12 and exon 55 and a commercially
available Taqman expression assay for beta actin (ACTB
Endogenous Control) (Applied Biosystems) were used.
Samples were analyzed in triplicate on the Applied Bio-
systems Prism 7900 system. The relative quantification
of the target sequences in respect to beta actin was per-
formed by the comparative CT method (ΔΔCT Method)
(Applied Biosystems User Bullettin #2); cDNAs from
two control females were used as calibrators. Each ex-
periment was performed in duplicate.
SPP1 Polymorphism Genotyping
17 out of 18 carriers were genotyped for the SPP1
(osteopontin) intragenic variant T/G in the promoter re-
gion (dbSNP: rs28357094). The polymerase chain reaction
was performed on genomic DNA using a specific pair of
primers (forward: 5’-AAGTGCTCTTCCTGGATGCTG-
3’; reverse: 5’-CTCCTGCTGCTGCTGACAAC-3’). All
PCRs were run in a final volume of 25 μl, containing
100 ng genomic DNA, 20 mM Tris–HCl (pH 8.4), 50 mM
KCl, 1.5 mmol/l MgCl2, 0.2 mmol/l dNTPs, 5U Taq DNA
Polymerase (Invitrogen) and 0.4 μl of each primer.
SDS–PAGE Electrophoresis and Immunoblotting Analysis
20-μm thick frozen muscle sections from each patient
and a control female were homogenized for 2 hours at
4°C with a RIPA lysis buffer containing: 50 mM Tris/HCl,
150 mM NaCl, 1 mM EDTA, 1% NP40, 0.1% SDS, 0.5%
deoxycholic acid, and an EDTA-free protease inhibitor
cocktail tablet (Roche), and then centrifuged at 1500 g for
10 min. Protein content was determined by the bicincho-
ninic acid method (Bicinchoninic protein assay, Pierce)
[26]. Equal amounts of protein (30 μg) were subjected to
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electrophoretically transferred to a nitrocellulose mem-
brane (100 V for 2 h). After transfer, the gel was stained
with Coomassie brilliant blue solution.
Membrane was blocked with non-fat dried milk for
1 h at room temperature and incubated overnight at 4°C
with the specific antibodies DYS2 (a mouse monoclonal
antibody to the carboxy terminal region of dystrophin,
1:200, NovoCastra, Newcastle, U.K.) and DYS1 (a mouse
monoclonal antibody to the rod domain of dystrophin,
1:500, NovoCastra, Newcastle, U.K.). After washing, the
membrane was incubated with horseradish peroxidase-
conjugated goat anti-mouse 1:40000, for 1 h at room
temperature. Immunocomplexes were visualized by
means of the ECL Advance Western Blotting Detection
Kit (Amersham Pharmacia Biotech, Buckinghamshire,
UK); exposure time on X-ray film was from less than
10 seconds to 1 minute. Densitometric analysis of auto-
radiographic bands was performed with a Bio-Rad densi-
tometer GS700 and expressed as absorbance (A).
Results
Eighteen females presenting a mosaic pattern of positive
and negative dystrophin fibres on muscle biopsy were
identified. These subjects were allocated to one of two
phenotype groups: (1) symptomatic and (2) asymptom-
atic, based on criteria reported in the Methods section.
Clinical data are summarized in Table 1. Among the
11 asymptomatic females, high serum CK levels were
detected in all cases, either alone or in association with
other minor myopathic signs like calf hypertrophy (in 5
females) or myalgia (in 1 female). Raised serum CK
levels were also detected to a significantly similar extent
in the 7 symptomatic females.
In this latter group, the age at symptom onset varied from
2 to 43 years. Muscle weakness was predominantly prox-
imal and symmetric. Echocardiographic examination was
performed in 9 females (2 symptomatic, 7 asymptomatic),
yielding results within normal limits in all cases.
One or more histopathological changes were observed
in all muscle biopsy samples: the most common findings
included variation in fibre size, increase in endomysial fi-
brous tissue, increased number of central nuclei, and
presence of necrosis and regeneration. Immunohisto-
chemical staining showed a mosaic pattern with popula-
tions of dystrophin-positive fibres, fibres with reduced or
discontinuous staining, and dystrophin-negative fibres
(Figure 1). Positive fibres count on multiple biopsy sec-
tions was not possible due to the limited amount of
muscle tissue available.
DMD Mutations in Female Carriers
Genomic analysis consented detection of the causative
DMD mutation in all subjects analysed (Table 2). 10deletions and 5 duplications of one or more exons were
identified by MLPA. Most deletions were clustered in
the distal hot-spot region of the gene; 8 were out-of-
frame and 2 extended beyond exon 79 (carriers 15 and
16). For female 16, carrying an exon-44-to-79 deletion,
CGH-array allowed us to determine the 3’ breakpoint,
and a large 3.5 Mb deletion, also including IL1RAPL-1
gene, was identified (Figure 2a).
Duplications were primarily located at the 5’-region of
the gene; 3 were out-of-frame and 1 represented by a
large in-frame duplication spreading from exon 3 to 44.
A non-contiguous duplication of exons 1P-7 and exons
13–42 was also identified by MLPA and confirmed by
CGH-array analysis (Figure 2b).
In two females negative for deletions and duplications,
nonsense mutations, occurring at exons 14 and 69, were
identified by sequencing.
The remaining female (carrier 1) presented a balanced
translocation involving chromosome Xp21.1 and chromo-
some 9; DMD-CGH-array showed normal dosage of the
DMD genomic locus (data not shown).
X-Inactivation Pattern in Skeletal Muscle
17 out of the 18 female carriers were found to be hetero-
zygous at the AR locus, and the X-inactivation pattern
was assessed (Table 2); two independent experiments
were performed with reproducible results. 4 symptom-
atic females showed clearly unbiased X-inactivation (car-
riers 2, 3, 6, and 7), 1 featured a moderately skewed
pattern (carrier 4), and 1 highly skewed X-inactivation
(carrier 1); among asymptomatic females, 6 showed ran-
dom X-inactivation (carriers 11, 12, 13, 16, 17, and 18),
4 a moderately skewed pattern (carriers 9, 10, 14, and
15), and 1 highly skewed X-inactivation (carrier 8). The
pattern obtained in the muscle DNA of the two highly
skewed samples (carriers 1 and 8) was compared with
that observed in their blood DNA. In carrier 1, bearing
the X;9 translocation, a total skewing of 100:0 was con-
firmed in blood, while the pattern observed in the
muscle of carrier 8 contrasted with the random inactiva-
tion observed in lymphocytes.
Transcriptional Behaviour of DMD Alleles
Transcriptional analysis was performed on muscle bi-
opsy samples from all subjects (Table 2).
All females, irrespective of their clinical status, showed
the same transcriptional behaviour, with the co-existence
of both wild-type and mutated transcripts.
The presence of biallelic transcripts was demonstrated
by RT-PCR in all subjects carrying deletions, with the
exception of females 15 and 16, who carry deletions
extending into the 3’-UTR. In these cases, the expression
of common polymorphisms of the DMD gene, found to
be heterozygous at genomic level, was evaluated: in
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13430 at 6y Normal 6y Quadriceps Moderate increase of endomysial fibrous
tissue, moderate number of necrotic fibers,
mild increase of internal nuclei, moderate
number of hypercontracted fibers.
C2 34y Symptomatic na Yes hCK 1050 at 34y Normal 34y Tibialis anterior Marked fiber size variation, moderate
increase of endomysial fibrous tissue,
increase of internal nuclei.






hCK Myalgia 2200 at 4y3m nd 4y Quadriceps Rare internal nuclei.









3034 at 25y nd 25y Quadriceps Marked fiber size variation, marked increase
of endomysial fibrous tissue, some necrotic
fibers.








hCK 933 at 43y nd 43y Left deltoid Moderate increase of endomysial fibrous
tissue, marked fiber size variation,
numerous internal nuclei.







714 at 27y nd 27y Quadriceps Marked fiber size variation, increase of
endomysial fibrous tissue, several internal
nuclei, some necrotic fibers.




6500 at 2y nd 9y Quadriceps Moderate fiber size variation, several
internal nuclei.
C8 20y Asymptomatic - No hCK Calves
hypertrophy
>4000 at 7y Normal 7y Quadriceps Moderate fiber size variation, hypotrophic
fibers and degenerating-regenerating fibers.
C9 34y Asymptomatic - No hCK Mild calves
hypertrophy
1654 at 16y Normal 9y Quadriceps Mild myopathic signs.
C10 35y Asymptomatic - No hCK (at 32y
and 35y)
Not reported nd 35y Quadriceps Moderate fiber size variation.
C11 47y Asymptomatic - No hCK 899 at 47y nd 47y Quadriceps Fiber size variation with hypertrophic fibers,
internal nuclei.
C12 24y Asymptomatic - No hCK Calves
hypertrophy



















Table 1 Clinical and biochemical data of symptomatic and asymptomatic female carriers (Continued)
C13 21y Asymptomatic - No hCK Calves
hypertrophy
10800 at 21y Left ventricle at
the upper limit
21y Quadriceps Moderate fiber size variation, increase of
endomysial fibrous tissue, numerous
internal nuclei, necrotic fibers.
C14 6y Asymptomatic - No hCK Myalgia 4439 at 6y Normal 6y Quadriceps Fiber type variation, central nuclei, absence
of inflammation.
C15 13y Asymptomatic - No hCK Learning
difficulties
1732 at 13y nd 13y Quadriceps Mild fiber size variation, increase in internal
nuclei.
C16 17y Asymptomatic - No hCK Mild calves
hypertrophy
2700 at 17y nd 3y Tibialis anterior Dystrophic pattern.
C17 5y Asymptomatic - No hCK 8207 at 2y Normal 2y Quadriceps Fiber size variation, mild increase of
endomysial fibrous tissue, some groups of
regenerating fibers.
C18 6y Asymptomatic - No hCK 10242 at 6y Normal 6y Quadriceps Moderate increase of endomysial fibrous
tissue, fiber size variation, several internal
nuclei, some degenerating fibers.


















Figure 1 Immunohistochemical staining of muscle sections from carriers 1 and 2. A) Immunolabeling in symptomatic carrier 1 with
NCL-DYS3 antibody (NH2-terminal) shows absence of staining in the majority of muscle fibers (approximately 80% in the whole section). B)
Immunolabeling in symptomatic carrier 2 with DYS2 antibody (COOH-terminal) shows a mosaic pattern of dystrophin expression with
coexistence of positive fibers, fibers with reduced or discontinuous staining and fibers with absence of labeling.
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c.5234G>A polymorphism in exon 37 demonstrated the
presence of a biallelic transcript; carrier 16 (del 44–79)
manifested biallelic expression of c.2645G>A polymor-
phism in exon 21 and monoallelic expression of c.5234G>A
polymorphism in exon 37. This unexpected transcriptional
behaviour could suggest the occurrence of splicing with an
unknown gene downstream of the deletion breakpoint and
the consequent generation of a chimeric transcript.
The presence of both wild-type and mutated tran-
scripts was assessed by RT-PCR in carriers presenting
duplications, with the exception of females 8 and 10;
amplification of the entire duplicated region was not
possible in carrier 10, but the presence of the mutated
transcript was however demonstrated by amplification of
the duplication junction (ex44-ex3). Due to the absence
of heterozygous exonic polymorphisms, we were only
able to infer the presence of the wild-type transcript. In
the subject possessing a non-contiguous duplication
(carrier 8), the presence of a biallelic transcript was
demonstrated by the biallelic expression of c.2645G>A
polymorphism in exon 21.
RNA studies in females 17 and 18, both carrying non-
sense mutations, showed the presence of both wild-type
and mutated transcripts.
In carrier 1, the presence of a biallelic transcript, com-
prising one originating from the normal X-chromosome
and one from the derivative X-chromosome, was
demonstrated by the biallelic expression of a rare poly-
morphism in the 3’-UTR of the gene (c.11058+22
del13nt). Since this variant was the only polymorphism
found to be heterozygous on genomic DNA, we could
not rule out the possibility that the observed biallelism
reflects the transcription of a 3’ isoform of dystrophin,
rather than the full-length RNA.
Semi-quantitative analysis (Table 2) revealed a preva-
lence of the wild-type transcript in 3 symptomatic (car-
riers 3, 5 and 6) and 3 asymptomatic (carriers 9, 13, and14) females and equal proportions of wild-type and
mutated mRNAs in 1 symptomatic (carrier 4) and 2
asymptomatic (carriers 11 and 12) females.
In the majority of cases, no relationship was found be-
tween the X-inactivation pattern and the transcriptional
level of dystrophin alleles (Figure 3 and Figure 4).
Eight carriers were further investigated by real-time
PCR in order to quantify the level of dystrophin tran-
scription, in respect to control females. Total transcript
quantification was performed by two different real-time
assays, on dystrophin exon 12 and exon 55 (Figure 5a).
The selected exons are not implicated in deletion or du-
plication in any of the carriers analyzed; the level of
wild-type transcript was derived from the relative ratio
of wild-type and mutated transcripts previously calcu-
lated (Figure 5b). No relationship was identified between
phenotype and dystrophin transcription level. Among
symptomatic carriers, the percentage of wild-type tran-
script ranged between 9% and 96% (exon 12 assay) and
between 6% and 69% (exon 55 assay), in respect to control
females; similar levels were observed among asymptom-
atic carriers, with wild-type transcript levels comprised
between 17% and 58% (exon 12 assay) and between 25%
and 63% (exon 55 assay), in respect to controls.
SPP1 Polymorphism Genotyping
Genotype analysis of the SPP1 variant was performed in
17 subjects; T allele homozygosity was revealed in 5 out
of 6 symptomatic carriers and T allele heterozygosity
was detected in only one. In the asymptomatic group, T
allele homozygosity was detected in 7 out of 11 subjects
and heterozygosity in 3 out of 11; the presence of an
homozygous G allele was found only in one asymptom-
atic carrier.
Western Blot Results
For carriers 1 and 8, both presenting skewed X-
inactivation but different phenotypes, we performed a
Table 2 Molecular characterization, X-inactivation pattern and transcriptional analysis results in symptomatic and asymptomatic carriers
Carrier
ID
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C10 Asymptomatic Dup exons 3–44
c.94-?_6438 + ?dup
(in frame)
85:15 DUP 3–44 transcript
(junction PCR)
nd nd nd












































Table 2 Molecular characterization, X-inactivation pattern and transcriptional analysis results in symptomatic and asymptomatic carriers (Continued)









C15 Asymptomatic Del exons 50–79
c.7201-?_(*2691_?)del
81:19 Biallelic transcript
(biallelic ex 37 SNP)
nd nd nd








C17 Asymptomatic c.1615C> T (ex 14)
p.R539X
42:58 WT+ 1615C> T
transcripts
nd nd nd
C18 Asymptomatic c.10033C > T (ex 69)
p.R3345X
70:30 WT+ 10033C > T
transcripts
nd nd nd
Sk.m.: skeletal muscle; WT: wild-type; MUT: mutated; nd: not determined.
a The DNA mutation numbering is based on cDNA sequence with a “c.” symbol before the number with +1 corresponding to the A of the ATG translation initiation codon in the respective reference sequence


















Figure 2 DMD-CGH array profile in carriers 16 and 8. A) In carrier 16, a deletion of 3.5 Mb was detected (chrX:g.(28.671.682_28.671.742)_
(32.170.481_32.170.541)del). The 5’ breakpoint is located within intron 43 of the DMD gene and deletion covers the following downstream genes:
FTHL17, MAP3K7IP3, GK, CXorf21, NR0B1, MAGEB4, MAGEB3, MAGEB2, MAGEB1, IL1RAPL1. B) In carrier 8, CGH analysis confirmed a non-contiguous
duplication involving exons 1P-7 (chrX:g.(33.068.711_33.068.771)_(32.684.693_32.684.750)dup) and exons 13–42 (chrX:g.(32.523.766_32.523.826)_
(32.228.415_32.228.475)dup). A polymorphic CNV is also visible within intron 2.
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quadriceps muscles via immunoblot using DYS2 and
DYS1 antibodies. This revealed the presence of a protein
of the correct size in both patient samples, but relative
quantification by densitometric analysis demonstrated
that muscles from subjects 1 (manifesting) and 8
(asymptomatic) contained, respectively, 15% and 70% of
normal, as compared to the control sample (Figure 6a).
These proportions were confirmed with DYS1 antibody,
which revealed 11% and 87% of normal protein levels for
carriers 1 and 8, respectively (Figure 6b).
Discussion
In order to shed light on the mechanism responsible for
the clinical manifestations in symptomatic female DMD
carriers, we recruited a cohort of 18 female carriers of a
mutation in the dystrophin gene, 7 symptomatic and 11
asymptomatic, and compared their genomic and tran-
scription profiles.In both symptomatic and asymptomatic females,
immunostaining of muscle biopsy tissue with anti-
dystrophin antibodies highlighted a mosaic pattern of
dystrophin-positive and dystrophin-negative fibres, in
addition to fibres with reduced dystrophin labelling.
Results reported by other groups showed no correlation
between the percentage of negative fibres and clinical
phenotype [17,27-29].
Skewed X-chromosome inactivation has been pro-
posed as a possible explanation for the presence of
symptoms in manifesting carriers; based on this hypoth-
esis, the X chromosome carrying the mutated dystrophin
gene should be active in the majority of nuclei in mus-
cles from symptomatic carriers.
X chromosome inactivation can be tested by different
methods. Methylation analysis at the androgen receptor
locus represents the most used assay: in contrast to dir-
ect methods based on expression analysis of poly-
morphic X-linked genes, AR assay is an indirect method
Figure 3 Comparison between X-inactivation pattern and transcript quantification. A) X-inactivation assay based on AR gene methylation.
The upper line corresponds to PCR products of undigested muscle DNA, showing the two alleles at AR locus; the lower shows the products of
DNA amplification after digestion with the methylation-sensitive enzymes HpaII and CfoI. B) RT-PCR analysis with a High Sensitivity DNA chip
(Agilent). The ratios between wild-type and mutated transcripts are indicated. Carrier 14 is an asymptomatic female with a moderately skewed
X-inactivation pattern of 87:13 and a transcript ratio of 65:35 (wt:deleted); symptomatic carrier 3 presented X-inactivation of 75:25 and a transcript
ratio of 70:30 (wt:duplicated); carrier 6 is a symptomatic female featuring random X-inactivation of 54:46 and transcript ratio of 89:11 (wt:deleted).
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X chromosome; however it is considered an accurate
test as high correlation has been demonstrated with
results obtained from direct expression analysis. Despite
the fact that several studies assessing the role of X-
inactivation have been performed, their findings have
been inconclusive and even contradictory. This disparityFigure 4 Schematic representation of results from X-inactivation and
X-inactivation studies and transcript quantification in the two groups of sym
a relationship between X-inactivation pattern, transcriptional behaviour andin results is partly due to the non-homogeneity of the
criteria adopted in different studies, such as the use of
different cut-off levels to define skewed X-inactivation
[15,19,21,25]. Furthermore, these studies have frequently
employed lymphocytes in evaluating X-inactivation, but
these cells fail to mirror dystrophin expression, and con-
siderable differences in X-inactivation pattern betweentranscriptional analysis. This schematic summarizes the results of
ptomatic and asymptomatic carriers, and highlights the absence of
dystrophic phenotype in female carriers.
Figure 5 Relative quantification of dystrophin transcript by
real-time PCR. A) Histograms represent total transcript level of
dystrophin gene in 8 female carriers, calculated on dystrophin exon
12 and exon 55, in respect to two control females (their mean value
referred as 100%). Error bars represent mean± SD. B) Transcriptional
level of wild-type dystrophin allele, calculated from the relative ratio
of wild-type and mutated transcripts.
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reported [21].
Nonetheless, the role of the X-inactivation pattern has
been demonstrated in females with X-autosome translocation;Figure 6 Immunoblotting in carriers 1 and 8 and Coomassie staining
Immunoblot with DYS2 antibody (directed against carboxy terminal region
carrier 8, with respect to control. B) Immunoblot with DYS1 antibody (direc
for carriers 1 and 8, respectively.cells featuring inactivation of the derivative X chromosome
become partially monosomic for the translocated autosome,
thereby conferring a selective advantage on cells having the
derivative X chromosome active. This is the situation in our
carrier 1, who features a balanced X;9 translocation; in this
case the totally skewed pattern of 100:0 observed in her blood
and muscle is not unexpected, and is in accordance with her
severe phenotype. However, the absence of dystrophin label-
ling in the majority of fibres (80%), but not all as would be
expected from a completely silenced normal X chromosome,
raises the question of how and where dystrophin-positive
fibres arise. Among the other symptomatic females inform-
ative for the polymorphism at the AR locus, the majority (4
out of 5) presented a random X-inactivation pattern, revealing
a lack of relationship between X-inactivation pattern and clin-
ical phenotype.
This is not surprising, as the absence of relationship
between X chromosome inactivation pattern and pheno-
type has been highlighted for other X-linked disorders:
in hemophilia A and B [30], Fabry disease [31] and
myotubular myopathy [32] the occurrence of disease
manifestations in females do not correlate with skewed
X-inactivation.
Genomic analysis was integrated with RNA studies
performed on muscle biopsy and revealed homogeneous
transcriptional behaviour; in all carriers, both symptom-
atic and asymptomatic, the transcription of both
mutated and wild-type mRNAs was observed. The coex-
istence of the two types of transcripts was demonstrated
in almost all cases, either directly by RT-PCR or indir-
ectly by the observation of the biallelic transcription of
polymorphism-containing exons. Unfortunately, the huge
size of the duplication and the absence of heterozygous
exonic polymorphisms precluded identification of this evi-
dence in carrier 10. Nonetheless, biallelic transcription
was demonstrated in carriers 15 and 16, despite the pres-
ence of large deletions extending into the 3’-UTR of the
gene, which might have reduced mRNA stability. In par-
ticular, we had the opportunity of further exploring carrierfor protein quantification by densitometric analysis. A)
of dystrophin) shows protein levels of 15% for carrier 1 and 70% for
ted against rod domain) reveals 11% and 87% of normal protein levels
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arrangement was thereby defined, and a 3.5 Mb deletion,
extending outside the DMD genomic locus, was identified.
In this case, the transcriptional behaviour seems to be very
complex, presumably involving the formation of a fusion
transcript comprising the DMD locus and another un-
identified adjacent gene. However the evidence of monoal-
lelic transcription of c.5234G>A polymorphism in
dystrophin exon 37 suggests that the fusion breakpoint on
the DMD gene transcript does not correspond to the
breakpoint of the genomic deletion, which is located in in-
tron 43.
The data gathered in the present study did highlight
the absence of any relationship between X-inactivation
pattern, transcriptional behaviour and dystrophic pheno-
type in females. Relative quantification of wild-type and
mutated transcripts was performed in 9 carriers, reveal-
ing no relationship with the X-inactivation pattern.
Among symptomatic females, this was particularly evi-
dent in carrier 4, characterized by skewed X-inactivation
and similar levels of the two transcripts, and carrier 6,
who, in contrast, was shown to possess a random X-
inactivation pattern but a strong prevalence of the wild-
type transcript. The absence of a relationship between
X-inactivation pattern and transcription was also evident
in asymptomatic carriers 11, 13, and 14.
The lack of relationship between phenotype and tran-
scriptional behaviour is also evident from our results;
among the 4 symptomatic carriers analysed with the
High Sensitivity Chip, 3 showed the prevalence of the
wild-type transcript over the mutated transcript, and 1
was characterized by similar levels of wild-type and
mutated mRNAs. This discrepancy between transcript
biallelic representation and X-inactivation strongly sug-
gests that other, probably genetic, determinants may in-
dependently influence dystrophin transcription and X
chromosome inactivation.
A genetic modifier of DMD severity in males has been
recently described [33]; the G allele of the rs28357094
polymorphism in the osteopontin (SPP1) promoter was
demonstrated to be associated with increased muscle
weakness and precocious loss of ambulation. Hence, we
analysed this variant in our series of carriers. Despite the
small size of the cohort precluding statistical signifi-
cance, we did find similar proportions of T and G alleles
in symptomatic (T allele: 11/12; G allele; 1/12) and
asymptomatic (T allele: 17/22; G allele: 5/22) subjects.
Relative quantification of wild-type and mutated alleles
was performed in females carrying out-of-frame muta-
tions; these results could therefore be biased by
nonsense-mediated decay of the mutated allele. In order
to overcome this problem, we performed a relative
quantification of wild-type transcript in respect to con-
trol females. Our data highlights the absence ofrelationship between phenotype and dystrophin tran-
scriptional level. With the exception of carrier 4, charac-
terized by very low dystrophin transcription rate (6-9%
in respect to controls), in the other cases the levels
quantified are very similar in symptomatic and asymp-
tomatic carriers.
A reduction in dystrophin protein abundance appears
to be a common feature in carriers: reduced protein
levels have been described both in symptomatic [17,28]
and asymptomatic females [21]. In our cohort of car-
riers, the manifesting female 1 for whom a precise pro-
tein quantification was performed showed a protein level
of less than 15% of normal abundance; quantification in
asymptomatic carrier 8 showed protein levels more than
70% of normal. These data raise the question of a pos-
sible relationship between dystrophin protein level and
phenotype. This issue will need to be addressed in future
studies of protein quantification with larger number of
carriers.
Conclusions
Considering our results along with those reported in
the literature, X-inactivation aetiology has been de-
finitively ruled out as an explanation of symptomatic
phenotype in female carriers. For the first time we
have shown that neither the transcriptional behaviour
of DMD gene enables prediction of a dystrophino-
pathic phenotype: no relationship between phenotype
and total DMD transcript level, or between phenotype
and relative proportion of the wild-type transcript
was observed in females. Interestingly, our study also
shows the absence of a relationship between X-
inactivation and transcriptional pattern of dystrophin,
suggesting that DMD gene escape, to some extent, X
chromosome inactivation. Our data suggest that the
key role in determining a symptomatic phenotype in
DMD female carriers may be played by the protein
amount, fact that deserves further fine quantitative
assays on larger patients cohort and relative muscle
samples.
Limitation section
Early age at clinical assessment
Three of the children in the asymptomatic group of
females (C14, C17 and C18) were examined at a
young age (6 years or younger), so that it is not pos-
sible to completely exclude that a phenotype will
compare at later ages. A comparison between age-
matched groups of carriers (symptomatic vs asymp-
tomatic) would be desirable. Despite this limitation,
even if we avoid to consider C14 (the unique young
girl studied for RNA behaviour) the general conclu-
sions of our analysis remain unchanged.
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We could provide Western blot data only for two
females: one symptomatic (C1) and one asymptomatic
(C8) carrier. No residual biopsy was available for females
other than C1 and C8, after immunohistochemical
analysis. The lack of extensive protein data represents a
limitation of the present work. Nevertheless, the existence
of a relationship between phenotype and dystrophin
protein levels (emerging from WB results in females C1
and C8) is largely supported by evidence in the literature.
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